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TO THE EDITOR
Eczema (Johansson et al., 2004) is a
common inflammatory skin disorder
associated with epidermal barrier
dysfunction (Jakasa et al., 2007). The
finding that null mutations within
the filaggrin gene (FLG) are strong
predisposing factors for atopic eczema
has been demonstrated and replicated
in multiple independent case–control
and association studies from different
European populations, as recently
reviewed by Irvine (2007). FLG is
located within the epidermal differen-
tiation complex on chromosome 1q21,
a cluster of genes involved in the
terminal differentiation of keratinocytes
(Mischke et al., 1996). FLG is expressed
in the granular layer of the stratum
corneum during terminal epidermal
differentiation. It aggregates the keratin
cytoskeleton to facilitate the collapse
and flattening of keratinocytes to pro-
duce squames (Manabe et al., 1991);
filaggrin may also contribute to epider-
mal barrier function following its degra-
dation to release hygroscopic amino
acids (Rawlings and Harding, 2004).
Detailed study of the structure and
function of the FLG gene has revealed
five prevalent null mutations within
the European population, as well as
multiple low-frequency null mutations,
some of which may be family specific
(Sandilands et al., 2007b). These
mutations have been found in 47% of
one eczema case series and together
they make a significant contribution to
the genetic susceptibility to atopic
eczema (Sandilands et al., 2007a).
Following on from a previous report
where the two most common FLG
mutations (R501X and 2282del4) were
strongly associated with early-onset
eczema persisting into adulthood
(Barker et al., 2007), we have extended
that case–control study to investigate
the significance of all five of the
recently described and most prevalent
FLG mutations. We studied a total of
186 adult eczema patients from London
and Newcastle-upon-Tyne, UK, whose
eczema had begun in early child-
hood. Their phenotypic characteristics
are as reported previously (Barker
et al., 2007). We similarly screened an
unselected population birth cohort
of 1,035 individuals from the northwest
of England, of unknown phenotype,
for use as a control population.
The study was carried out in accor-
dance with the Declaration of HelsinkiAbbreviation: FLG, filaggrin gene
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Principles and approved by the local
Research Ethics Committees in London
and Newcastle. All subjects or the
subjects’ guardians gave informed con-
sent. Mutation analysis was performed
using a TaqMan-based allelic discrimi-
nation assay (Applied Biosystems, Fos-
ter City, CA) for R501X, 2282del4,
R2447X, and S3247X and size analysis
of fluorescently labeled PCR products
using an Applied Biosystems 3100
DNA sequencer for 3702delG, as de-
scribed previously (Palmer et al., 2006;
Sandilands et al., 2006). Homozygote
and heterozygote results were con-
firmed by restriction enzyme digest
(Palmer et al., 2006; Sandilands et al.,
2006) or sequencing (Sandilands et al.,
2007b). Allele and genotype frequen-
cies were compared by Fisher’s exact
test and logistic regression, using the
statistical analysis package Stata
(StataCorp LP, College Station, TX).
Exploratory haplotype analysis was
performed using the software package
UNPHASED (Dudbridge, 2007).
In this study population, three of
the common FLG variants are strongly
and independently associated with
early-onset persistent eczema: R501X
(P¼3.21017, odds ratio (OR) 5.6,
95% confidence interval (95% CI)
3.7–8.3), 2282del4 (P¼7.1 1010,
OR 4.1, 95% CI 2.7–6.4), and R2447X
(P¼7.8105, OR 7.3, 95% CI
2.8–18.7). Sequencing of the PCR frag-
ment produced by the assay for
3702delG identified a novel, previously
unreported single base-pair deletion,
3673delC, within the third filaggrin
repeat. This mutation was found in
one of the eczema cases (a compound
heterozygote with R501X) but was not
identified in any of the controls.
The rarer S3247X, 3702delG, and
3673delC variants were not signifi-
cantly associated with eczema when
analyzed individually. However, the
combined null genotype of all six
mutations showed a highly significant
association (P¼1.3 1028, OR 5.6,
95% CI 4.1–7.8). As the control popula-
tion consists of individuals with un-
known phenotype and an estimated
prevalence of 23–25% atopic eczema
(Shamssain, 2007), the true association
may in fact be even more highly
significant. In total, 45.7% of cases
carried one or more of the filaggrin
mutations, compared with 11.5% of the
control population. This is therefore
very comparable to the recent study of
these mutations in an Irish pediatric
eczema case–control study, where
47% of cases carried FLG mutations
(Sandilands et al., 2007b).
The figures shown in Table 1 result
from statistical calculations assuming a
genotype-based model of disease, test-
ing to what extent the genotypes (AA,
Aa, or aa) can predict the disease status
(case or control). An alternative statis-
tical model may also be used, based on
alleles, assuming a multiplicative mod-
el, that is the presence of two copies of
the null allele (aa) will give twice the
effect of one copy on the log odds scale
(Aa; Table 2). Comparison of the two
models using a likelihood ratio test
shows that there is no significant
difference (for example, P¼ 0.7 for the
R501X variant), indicating that either
model can appropriately be used.
The genotype-based analysis allows
us to compare the estimated effect of
carrying one mutation with the esti-
mated effect of carrying two mutations,
where homozygotes are present
(Table 2). The CIs are large and over-
lapping, but it can be seen that homo-
zygote mutants for R501X tend to have
a higher OR of disease than hetero-
zygotes when compared with wild-type
homozygotes. More strikingly, although
the CIs are again wide, the combined
null genotype shows an OR of 85.9
(95% CI 20.1–367.6) for homozygotes
and compound heterozygotes, as op-
posed to 4.6 (3.1–6.8) for hetero-
Table 1. FLG genotypes in English adult cases of early-onset persistent atopic eczema and an unselected population
control group
R501X 2282del4 R2447X S3247X 3702delG 3673delC
Combined null
genotype
Geno-
type
Control
population
Atopic
eczema
cases
Control
population
Atopic
eczema
cases
Control
population
Atopic
eczema
cases
Control
population
Atopic
eczema
cases
Control
population
Atopic
eczema
cases
Control
population
Atopic
eczema
cases
Control
population
Atopic
eczema
cases
AA 943 138 899 150 1,014 174 791 183 880 183 881 183 661 100
Aa 52 39 52 32 8 10 4 1 1 1 0 1 84 58
aa 1 9 0 4 0 0 0 0 0 0 0 0 2 26
Total 996 186 951 186 1,022 184 795 184 881 184 881 184 747 184
P=3.2 1017 P=7.11010 P=7.8 105 P=1.0 P=0.3 P=0.2 P=1.3 1028
AA, homozygous wild type for FLG null mutation; Aa, heterozygous for any one of the FLG null mutations; aa, homozygous for each of the six FLG null
mutations studied and/or compound heterozygous for any of the null mutations in the ‘‘combined null genotype’’ data. The rationale for generating this
combined genotype is based on the fact that each mutation results in premature termination of the profilaggrin molecule and hence absence of processed
filaggrin (Sandilands et al., 2007b).
Each variant was in Hardy–Weinberg equilibrium in the control population with the exception of 3673delC, because there is insufficient data to allow this
calculation.
In the control population, there was one homozygote (R501X) and one compound heterozygote (R501X/2282del4). Among the eczema cases, there were 12
homozygotes (eight for R501X and four for 2282del4) and 13 compound heterozygotes (eight R501X/2282del4, three R501X/R2447X, one R501X/3673delC,
and one 2282del4/R2447X).
The total figures vary because of incomplete genotyping results; all available data has been used for optimal analysis of each individual variant, but the
combined null genotype data include only those individuals for whom all six genotype results are available.
P-values are calculated using the Fisher’s exact test.
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zygotes. In other words, an individual
carrying one of these six null mutations
has an approximately four times greater
chance of having early-onset persistent
eczema, whereas carriage of two FLG
null mutations increases the risk about
80 times, when compared with an
individual who does not carry any of
these variants. These data support the
clinical observations reported in the
original cohort studies of ichthyosis
vulgaris and atopic eczema, suggesting
that FLG mutations are semidominant
(Palmer et al., 2006; Smith et al., 2006).
The genotype-based analysis (Table 2)
also demonstrates a significant associa-
tion between heterozygote status and
eczema, independent of the homo-
zygotes and compound heterozygotes,
a group likely to contain a large pro-
portion of individuals with ichthyosis
vulgaris and severe eczema.
Comparison of the ORs associated
with different mutations has been used
as an estimate of their relative strength
of effect in influencing the skin pheno-
type. In this way, it has been suggested
that the S3247X mutation (which
occurs in repeat 9 of exon 3) may be
less penetrant than other mutations that
occur in earlier repeats (Sandilands
et al., 2007b). However, a more sophis-
ticated statistical technique can be
used—the test of equality of haplotype
risks—to test the risk of disease asso-
ciated with different mutations. Analyz-
ing our data in this way has shown that
there is no significant difference in the
risk associated with R501X and
2282del4 (P¼ 0.2) or R501X and
R2447X (P¼0.6). However, there is a
trend towards significance when com-
paring the risks associated with R501X
and S3247X (P¼0.07). This is in keeping
with different ORs associated with
these variants in the original report
(Sandilands et al., 2007b). This may
be explained either by the fact that
S3247X allows partial expression of
profilaggrin or because it is in linkage
disequilibrium with a protective factor
nearby in the epidermal differentiation
complex (Sandilands et al., 2007b). As
it has been shown biochemically both
in mouse (Presland et al., 2000) and
humans (Sandilands et al., 2007b) that
distal FLG null mutations are equivalent
in terms of preventing profilaggrin-
to-filaggrin processing as well as
destabilizing the truncated proprotein,
the latter hypothesis is perhaps more
likely. However, in this study, it is
difficult to draw firm conclusions, as
the S3247X mutation may not have
shown significant association with the
eczema phenotype owing to its low
frequency and the presence of eczema
cases within the unphenotyped control
group.
It has been reasoned from first princi-
ples that a compound heterozygote
individual is likely to carry one FLG
mutation on each chromosome. How-
ever, it would theoretically be possible
for two mutations to occur on the same
chromosome, although clearly the muta-
tion occurring downstream of a null
mutation would not have any additional
effect on protein expression. This possi-
bility was tested statistically by haplotype
analysis (Dudbridge, 2007). In our group
of cases and controls, the probability of
any two mutations occurring in the same
phase (that is, on the same chromosome)
is vanishingly small, with estimated
haplotype frequencies o1010.
In conclusion, this study has demon-
strated that the three most prevalent null
mutations in FLG (R501X, 2282del4,
and R2447X) are significantly and in-
dependently associated with the pheno-
type of early-onset atopic eczema
that recurs or persists into adulthood.
Together with three lower-frequency
null mutations (S3247X, 3702delG,
and 3673delC), they make a significant
contribution to the genetic susceptibility
to this severe eczema phenotype.
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Table 2. Results of logistic regression analysis to calculate ORs using the genotype and allele-based models
R501X 2282del4 R2447X S3247X 3702delG 3673delC
Combined
null genotype
OR calculated using the
allele model (95% CIs)
5.6 (3.7–8.3) 4.1 (2.7–6.4) 7.3 (2.8–18.7) 1.1 (0.1–9.7) 4.8 (0.3–77.2) NA 5.6 (4.1–7.8)
OR calculated using the genotype model (95% CIs)
Heterozygotes vs wild type 5.1 (3.3–8.1) 3.7 (2.3–5.9) 7.3 (2.8–18.7) 1.1 (0.1–9.7) 4.8 (0.3–77.2) NA 4.6 (3.1–6.8)
Homozygote mutants vs wild type 61.5 (7.7–489.2) NA NA NA NA NA 85.9 (20.1–367.6)
CI, confidence interval; NA, not analyzed, because of absence or insufficient numbers of homozygotes (and heterozygotes for delC); OR, odds ratio.
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TO THE EDITOR
Allergic diseases typically develop in
mucosal surfaces such as the skin,
airway and gastrointestinal tract. The
best described of these are atopic
dermatitis (AD), food allergy, allergic
rhinitis (AR), and asthma. More re-
cently, eosinophilic esophagitis (EE)
has also been characterized as an
atopic disorder. Genetic studies have
highlighted the importance of epithe-
lial-derived genes such as dipeptidyl
peptidase 10, serine protease inhibi-
tor–kazal-type 5, stratum corneum chy-
motryptic enzyme, and filaggrin (FLG)
in either asthma or AD or both (Morar
et al., 2006). Specific loss-of-function
mutations in the FLG gene recently
described in subjects with AD are
thought to explain, in part, the cuta-
neous barrier defects long observed in
AD (Palmer et al., 2006). Stratum
granulosum cells produce filaggrin as
they differentiate into stratum corneum
cells. Filaggrin aggregates keratin fila-
ments within the cells resulting in the
cornified envelope, which is critical for
barrier function. This work has led
many to hypothesize that the skin is a
key portal of entry for relevant allergens
and irritants that can drive both skin
and airway disease (Cork et al., 2006).
This is further supported by the evi-
dence that FLG mutations are asso-
ciated with extrinsic AD, early onset of
eczema that persists into adulthood,
and the coexistence of atopic asthma or
AR and AD (Marenholz et al., 2006;
Palmer et al., 2006; Weidinger et al.,
2007). This latter association has led to
the speculation that FLG mutations may
directly impact barrier function at other
mucosal surfaces such as airway or
gastrointestinal tracts. The mucosal
surfaces where filaggrin is expressed
have not been well characterized. An
online textbook and previous published
studies state that filaggrin immunoreac-
tivity has been observed in orthokerati-
nized and parakeratinized areas of
human oral epithelium (Smith and
Dale, 1986; Reibel et al., 1989), cervix,
endometrium, and vagina (http://
www.proteinatlas.org/tissue_profile.php?
antibody_id=2210). Whether mutations
in FLG would have a direct impact on
barrier function in other mucosal sur-
faces such as upper airway and eso-
phagus has not been well studied. To
address the lower airway, Ying et al.
(2006) recently reported the complete
absence of filaggrin immunoreactivity
in bronchial biopsies obtained from
both asthmatic and nonatopic (NA)
control subjects. Bronchial staining
(n¼3) conducted in our laboratory
have confirmed Ying’s findings (data
not shown). This data suggests that
filaggrin has no direct role in lower
Abbreviations: AD, atopic dermatitis; AR, allergic rhinitis; EE, eosinophilic esophagitis; FLG, filaggrin;
IRB, Institutional Review Board; NA, nonatopic
1594 Journal of Investigative Dermatology (2008), Volume 128
AD Benedetto et al.
Filaggrin Expression
